我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Alcobra Ltd.
相关临床试验
17
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
3
17.6%
已完成
8
47.1%
招募中
终止
暂无批准数据
- The global mRNA cancer vaccine market is projected to exceed $1.20 billion in 2026, driven by precision medicine innovations and late-stage clinical validation. - Personalized and off-the-shelf mRNA platforms are gaining traction across multiple tumor types, including high-TMB solid tumors, GI cancers, and breast cancers. - North America leads the market due to advanced infrastructure, while Asia Pacific is expected to register the fastest growth through 2036. - Key players such as Moderna, BioNTech, and Arcturus Therapeutics are shaping the competitive landscape through strategic alliances and manufacturing scale-up.
